vs

Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and UNITED FIRE GROUP INC (UFCS). Click either name above to swap in a different company.

Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($722.5M vs $365.8M, roughly 2.0× UNITED FIRE GROUP INC). On growth, UNITED FIRE GROUP INC posted the faster year-over-year revenue change (9.8% vs 3.9%). Over the past eight quarters, UNITED FIRE GROUP INC's revenue compounded faster (11.2% CAGR vs 1.5%).

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

The United Fruit Company was an American multinational corporation that traded in tropical fruit grown on Latin American plantations and sold in the United States and Europe. The company was formed in 1899 from the merger of the Boston Fruit Company with Minor C. Keith's banana-trading enterprises. It flourished in the early and mid-20th century, and it came to control vast territories and transportation networks in Central America, the Caribbean coast of Colombia, and the West Indies. Althou...

AMRX vs UFCS — Head-to-Head

Bigger by revenue
AMRX
AMRX
2.0× larger
AMRX
$722.5M
$365.8M
UFCS
Growing faster (revenue YoY)
UFCS
UFCS
+5.9% gap
UFCS
9.8%
3.9%
AMRX
Faster 2-yr revenue CAGR
UFCS
UFCS
Annualised
UFCS
11.2%
1.5%
AMRX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRX
AMRX
UFCS
UFCS
Revenue
$722.5M
$365.8M
Net Profit
$78.0M
Gross Margin
44.3%
Operating Margin
19.6%
13.2%
Net Margin
10.8%
Revenue YoY
3.9%
9.8%
Net Profit YoY
410.5%
EPS (diluted)
$0.19
$1.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRX
AMRX
UFCS
UFCS
Q1 26
$722.5M
Q4 25
$814.3M
$365.8M
Q3 25
$784.5M
$354.0M
Q2 25
$724.5M
$335.5M
Q1 25
$695.4M
$331.1M
Q4 24
$730.5M
$333.2M
Q3 24
$702.5M
$323.0M
Q2 24
$701.8M
$301.2M
Net Profit
AMRX
AMRX
UFCS
UFCS
Q1 26
$78.0M
Q4 25
$35.1M
Q3 25
$2.4M
$39.2M
Q2 25
$22.4M
$22.9M
Q1 25
$12.2M
$17.7M
Q4 24
$-31.1M
Q3 24
$-156.0K
$19.7M
Q2 24
$6.0M
$-2.7M
Gross Margin
AMRX
AMRX
UFCS
UFCS
Q1 26
44.3%
Q4 25
36.5%
Q3 25
34.9%
Q2 25
39.5%
Q1 25
36.8%
Q4 24
36.0%
Q3 24
38.4%
Q2 24
35.6%
Operating Margin
AMRX
AMRX
UFCS
UFCS
Q1 26
19.6%
Q4 25
13.8%
13.2%
Q3 25
9.0%
13.7%
Q2 25
15.4%
8.7%
Q1 25
14.4%
6.6%
Q4 24
10.4%
11.9%
Q3 24
12.6%
7.7%
Q2 24
13.6%
-1.3%
Net Margin
AMRX
AMRX
UFCS
UFCS
Q1 26
10.8%
Q4 25
4.3%
Q3 25
0.3%
11.1%
Q2 25
3.1%
6.8%
Q1 25
1.8%
5.3%
Q4 24
-4.3%
Q3 24
-0.0%
6.1%
Q2 24
0.9%
-0.9%
EPS (diluted)
AMRX
AMRX
UFCS
UFCS
Q1 26
$0.19
Q4 25
$0.10
$1.45
Q3 25
$0.01
$1.49
Q2 25
$0.07
$0.87
Q1 25
$0.04
$0.67
Q4 24
$-0.10
$1.22
Q3 24
$0.00
$0.76
Q2 24
$0.02
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRX
AMRX
UFCS
UFCS
Cash + ST InvestmentsLiquidity on hand
$197.7M
$156.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$941.2M
Total Assets
$3.5B
$3.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRX
AMRX
UFCS
UFCS
Q1 26
$197.7M
Q4 25
$282.0M
$156.3M
Q3 25
$201.2M
$233.7M
Q2 25
$71.5M
$202.1M
Q1 25
$59.2M
$183.7M
Q4 24
$110.6M
$200.9M
Q3 24
$74.0M
$197.4M
Q2 24
$43.8M
$153.4M
Total Debt
AMRX
AMRX
UFCS
UFCS
Q1 26
Q4 25
$2.6B
Q3 25
$2.6B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Stockholders' Equity
AMRX
AMRX
UFCS
UFCS
Q1 26
Q4 25
$-70.8M
$941.2M
Q3 25
$-109.5M
$898.7M
Q2 25
$-112.1M
$845.7M
Q1 25
$-131.7M
$817.7M
Q4 24
$-109.3M
$781.5M
Q3 24
$-93.4M
$785.8M
Q2 24
$-57.5M
$726.6M
Total Assets
AMRX
AMRX
UFCS
UFCS
Q1 26
$3.5B
Q4 25
$3.7B
$3.8B
Q3 25
$3.6B
$3.8B
Q2 25
$3.4B
$3.7B
Q1 25
$3.4B
$3.5B
Q4 24
$3.5B
$3.5B
Q3 24
$3.5B
$3.5B
Q2 24
$3.5B
$3.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRX
AMRX
UFCS
UFCS
Operating Cash FlowLast quarter
$269.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRX
AMRX
UFCS
UFCS
Q1 26
Q4 25
$130.3M
$269.7M
Q3 25
$118.5M
$60.8M
Q2 25
$83.8M
$53.4M
Q1 25
$7.4M
$35.7M
Q4 24
$118.1M
$340.3M
Q3 24
$141.8M
$56.5M
Q2 24
$39.7M
$91.3M
Free Cash Flow
AMRX
AMRX
UFCS
UFCS
Q1 26
Q4 25
$108.5M
Q3 25
$106.2M
Q2 25
$61.0M
Q1 25
$-5.8M
Q4 24
$102.9M
Q3 24
$124.8M
Q2 24
$29.0M
FCF Margin
AMRX
AMRX
UFCS
UFCS
Q1 26
Q4 25
13.3%
Q3 25
13.5%
Q2 25
8.4%
Q1 25
-0.8%
Q4 24
14.1%
Q3 24
17.8%
Q2 24
4.1%
Capex Intensity
AMRX
AMRX
UFCS
UFCS
Q1 26
Q4 25
2.7%
Q3 25
1.6%
Q2 25
3.2%
Q1 25
1.9%
Q4 24
2.1%
Q3 24
2.4%
Q2 24
1.5%
Cash Conversion
AMRX
AMRX
UFCS
UFCS
Q1 26
Q4 25
3.72×
Q3 25
50.00×
1.55×
Q2 25
3.74×
2.33×
Q1 25
0.61×
2.02×
Q4 24
Q3 24
2.86×
Q2 24
6.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons